Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 19;13(12):e0209148.
doi: 10.1371/journal.pone.0209148. eCollection 2018.

Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea: A nationwide study based on the health insurance review and assessment service database

Shinjeong Song  1 , Sang-Eun Lee  1   2 , Sang Kwon Oh  3 , Seong A Jeon  1   2 , Ji Min Sung  1   2 , Jae-Hyeong Park  4 , Hyuk-Jae Chang  1   2   5
Affiliations

Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea: A nationwide study based on the health insurance review and assessment service database

Shinjeong Song et al. PLoS One. .

Abstract

Epidemiologic data regarding pulmonary arterial hypertension (PAH) have relied on registries from Western countries. We assessed the current status of PAH in the Korean population. The Health Insurance Review and Assessment Service (HIRA) claim database, which comprises nationwide medical insurance data of Koreans from 2008-2016, was assessed to determine the current status of PAH. Overall, 1,307 patients were newly diagnosed with PAH from 2008-2016 (0.0005%, annual incidence: 4.84 patients/1 million people/year). The mean age at diagnosis was 44±13 years (range 18-65) and patients were mostly women (n = 906, 69.3%). Cases of idiopathic PAH (51.6%) accounted for the largest proportion, followed by acquired PAH (APAH) associated with congenital heart disease (25.8%) and APAH with connective tissue disease (17.2%). Overall, 807 (61.7%) patients received a single PAH-specific treatment based on their last prescription, of which bosentan (50.6%) was the most frequently used. Only 240 (18.4%) patients received combination therapy, with the bosentan-beraprost combination (32.9%) being the most common. During the mean follow-up of 1.9 years, the 1-, 2-, 3-, and 5-year estimated survival rates were 85%, 62%, 54%, and 46%, respectively. The prevalence and incidence of PAH in the Korean population is currently comparable with that in previous registries. The 5-year survival rate was slightly higher in the Korean population than previously reported.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Inclusion flow diagram of newly diagnosed pulmonary arterial hypertension patients enrolled in the study.
PAH, pulmonary arterial hypertension; ICD-10, International Classification of Diseases-Tenth Revision.
Fig 2
Fig 2. Pulmonary arterial hypertension etiological breakdown of patients at enrolment.
Fig 3
Fig 3. Cumulative survival curve of patients with pulmonary arterial hypertension.
(A) The 1-year, 2-year, and 3-year estimated survival rates shown are 84.9%, 62.2%, and 54.3%, respectively. (B). Primary outcome: cumulative survival curve of patients with pulmonary arterial hypertension according to etiology. IPAH, idiopathic pulmonary arterial hypertension; APAH, acquired pulmonary arterial hypertension.
Fig 4
Fig 4. Distribution and trend of prescribed pulmonary arterial hypertension-specific drugs.
Fig 5
Fig 5. The trend of right catheter catheterization according to etiology in newly diagnosed patients per year.
IPAH, idiopathic pulmonary arterial hypertension; APAH, acquired pulmonary arterial hypertension.
See this image and copyright information in PMC

References

    1. Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336: 111–117. 10.1056/NEJM199701093360207 - DOI - PubMed
    1. Farber HW, Loscalzo J (2004) Pulmonary arterial hypertension. N Engl J Med 351: 1655–1665. 10.1056/NEJMra035488 - DOI - PubMed
    1. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, et al. (2004) Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126: 14S–34S. 10.1378/chest.126.1_suppl.14S - DOI - PubMed
    1. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, et al. (2004) Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126: 78S–92S. 10.1378/chest.126.1_suppl.78S - DOI - PubMed
    1. Barst RJ (2001) Medical therapy of pulmonary hypertension. An overview of treatment and goals. Clin Chest Med 22: 509–515, ix. - PubMed